FibroGen Company Profile (NASDAQ:FGEN)

About FibroGen

FibroGen logoFibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FGEN
  • CUSIP:
Key Metrics:
  • Previous Close: $17.65
  • 50 Day Moving Average: $19.73
  • 200 Day Moving Average: $18.61
  • 52-Week Range: $14.38 - $31.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.91
  • P/E Growth: 0.00
  • Market Cap: $1.11B
  • Outstanding Shares: 62,788,000
  • Beta: 1.29
  • Net Margins: -61.90%
  • Return on Equity: -48.66%
  • Return on Assets: -20.92%
  • Debt-to-Equity Ratio: 0.46%
  • Current Ratio: 3.80%
  • Quick Ratio: 3.80%
Additional Links:
Companies Related to FibroGen:

Analyst Ratings

Consensus Ratings for FibroGen (NASDAQ:FGEN) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $36.00 (103.97% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
DateFirmActionRatingPrice TargetDetails
8/9/2016Credit Suisse Group AGReiterated RatingBuy$37.00View Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$34.00 -> $31.00View Rating Details
12/29/2015Leerink SwannReiterated RatingBuyView Rating Details
12/4/2015Citigroup Inc.Initiated CoverageBuy$40.00View Rating Details
9/23/2015Lake Street CapitalInitiated CoverageHold$25.00View Rating Details
12/9/2014Stifel NicolausInitiated CoverageBuy$39.00View Rating Details
12/9/2014Royal Bank Of CanadaInitiated CoverageOutperform$38.00View Rating Details
12/8/2014William BlairInitiated CoverageOutperformView Rating Details
(Data available from 10/21/2014 forward)


Earnings History for FibroGen (NASDAQ:FGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q2$0.36$0.35ViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$17.74 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)ViewListenView Earnings Details
11/12/2015Q3($0.61)($0.74)ViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.52)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for FibroGen (NASDAQ:FGEN)
Current Year EPS Consensus Estimate: $-1.39 EPS
Next Year EPS Consensus Estimate: $-1.98 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.84)($0.59)($0.70)
Q2 20164$0.15$0.43$0.30
Q3 20163($0.76)($0.52)($0.64)
Q4 20163($0.74)($0.68)($0.70)
Q1 20171($0.67)($0.67)($0.67)
Q2 20171($0.67)($0.67)($0.67)
Q3 20171($0.68)($0.68)($0.68)
Q4 20171($0.75)($0.75)($0.75)
(Data provided by Zacks Investment Research)


Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for FibroGen (NASDAQ:FGEN)
Insider Ownership Percentage: 14.90%
Institutional Ownership Percentage: 49.78%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.50View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.06View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.33View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.45View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.68View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.02View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.40View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.24View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.00View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.00View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.00View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.00View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.00View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.00View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.00View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.00View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.00View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.00View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.00View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.00View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.00View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.50View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.00View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.00View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.00View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.00View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.00View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.14View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.00View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.00View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.00View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.00View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.00View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.00View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.00View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.00View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.00View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.00View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.00View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.00View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.00View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for FibroGen (NASDAQ:FGEN)
News IconLooking Ahead for FibroGen, Inc (NASDAQ:FGEN); Are These Shares Ready to Go Higher? - CSZ News (NASDAQ:FGEN) - October 18 at 4:57 PM
News IconA Screaming Buy? Analyst's Take on FibroGen, Inc. (NASDAQ:FGEN) - Recall News (NASDAQ:FGEN) - October 17 at 4:58 PM
News IconLatest Analyst Ratings For FibroGen, Inc (NASDAQ:FGEN) - The De Soto Edge (NASDAQ:FGEN) - October 16 at 9:38 AM
News IconShare Value Diminishing Over Past Month: FibroGen, Inc. (NASDAQ:FGEN) - CSZ News (NASDAQ:FGEN) - October 16 at 9:38 AM logoETF’s with exposure to FibroGen, Inc. : October 14, 2016 (NASDAQ:FGEN) - October 14 at 4:54 PM logoFibroGen, Inc (NASDAQ:FGEN) Sales Estimate At $1055.435 - Investor Newswire (NASDAQ:FGEN) - October 14 at 8:03 AM logoFibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : October 13, 2016 (NASDAQ:FGEN) - October 13 at 12:43 PM
News IconInsider Selling: FibroGen Inc. (FGEN) CEO Sells $388374.45 in Stock - DailyQuint (NASDAQ:FGEN) - October 12 at 9:58 AM
News IconFibroGen, Inc (NASDAQ:FGEN) Updated Broker Price Targets (NASDAQ:FGEN) - September 30 at 10:07 AM
News IconFibroGen, Inc (NASDAQ:FGEN) Updated Broker Price Targets - The De Soto Edge (NASDAQ:FGEN) - September 29 at 4:56 PM
News IconNoticeable Price Move: Harvard Bioscience, Inc. (NASDAQ:HBIO) , FibroGen, Inc (NASDAQ:FGEN) - Wall Street Times (press release) (NASDAQ:FGEN) - September 28 at 4:52 PM logoFibroGen, Inc (NASDAQ:FGEN) Is Expected To Post EPS Of $-0.68 - (NASDAQ:FGEN) - September 28 at 4:52 PM logoETF’s with exposure to FibroGen, Inc. : September 28, 2016 (NASDAQ:FGEN) - September 28 at 9:54 AM logoFibroGen, Inc (NASDAQ:FGEN) EPS Estimate At $-0.68 - Investor Newswire (NASDAQ:FGEN) - September 25 at 4:33 PM
News IconExpert Analysts Position for: LKQ Corporation (NASDAQ:LKQ) , FibroGen, Inc (NASDAQ:FGEN) - Wall Street Times (press release) (NASDAQ:FGEN) - September 21 at 9:15 AM
News IconFibroGen Inc (FGEN) Trading Down 2.9% on Insider Selling - DailyQuint (NASDAQ:FGEN) - September 19 at 3:56 PM
News IconStock Trending Alert: FibroGen, Inc (NASDAQ:FGEN) , HNI Corporation (NYSE:HNI) - Wall Street Times (press release) (NASDAQ:FGEN) - September 17 at 4:50 PM logoExpected For FibroGen, Inc (NASDAQ:FGEN) Sales Of $1055.435 - Investor Newswire (NASDAQ:FGEN) - September 16 at 8:47 AM
News IconAnalysts Take: FibroGen, Inc (NASDAQ:FGEN) Projected Earnings & Price Targets - Frisco Fastball (NASDAQ:FGEN) - September 12 at 4:52 PM logoFibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : September 7, 2016 (NASDAQ:FGEN) - September 7 at 8:21 AM
News IconShares Slipping Lower Over the Past Month: FibroGen, Inc. (NASDAQ:FGEN) - Post News (NASDAQ:FGEN) - September 1 at 5:48 AM logoFibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : August 26, 2016 (NASDAQ:FGEN) - August 26 at 4:54 PM logoFibroGen, Inc (NASDAQ:FGEN) Reports Sales Of $89.28, Surprising Estimates By 10.796% - Investor Newswire (NASDAQ:FGEN) - August 25 at 5:01 PM logoNewly released market study: FibroGen, Inc. (FGEN) - Financial and Strategic SWOT Analysis Review (NASDAQ:FGEN) - August 24 at 4:55 PM logoETF’s with exposure to FibroGen, Inc. : August 23, 2016 (NASDAQ:FGEN) - August 23 at 5:06 PM
News IconFibroGen, Inc (NASDAQ:FGEN) Shares in Focus According to the Crowd & Analysts - Post News (NASDAQ:FGEN) - August 23 at 9:22 AM logoAnalysts See Sales Of $1055.435 For FibroGen, Inc (NASDAQ:FGEN) - Investor Newswire (NASDAQ:FGEN) - August 19 at 5:47 AM logoFIBROGEN INC Financials (NASDAQ:FGEN) - August 17 at 5:11 PM logoFibroGen, Inc. :FGEN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:FGEN) - August 12 at 5:02 PM logoFibroGen, Inc (NASDAQ:FGEN) Records An Estimated Annual Sales Mean Of $1055.435 - Investor Newswire (NASDAQ:FGEN) - August 12 at 8:01 AM logoBlackrock Fund Advisors Marginally Increases Its Ownership in FibroGen, Inc (FGEN) Stock Last Quarter - Finance Daily (NASDAQ:FGEN) - August 11 at 5:29 AM logoEdited Transcript of FGEN earnings conference call or presentation 8-Aug-16 8:30pm GMT (NASDAQ:FGEN) - August 9 at 3:43 PM logoFibroGen beats Street 2Q forecasts (NASDAQ:FGEN) - August 8 at 10:23 PM logoFibroGen Reports Financial Results for the Second Quarter of 2016 (NASDAQ:FGEN) - August 8 at 5:10 PM logoFIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:FGEN) - August 8 at 5:10 PM logoFibroGen Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:FGEN) - August 8 at 5:10 PM logoQ2 2016 FibroGen Inc Earnings Release - After Market Close (NASDAQ:FGEN) - August 8 at 9:49 AM logoFibroGen to Report Second Quarter 2016 Financial... (NASDAQ:FGEN) - August 2 at 10:36 PM logoFibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016 (NASDAQ:FGEN) - August 2 at 10:36 PM logoFibroGen, Inc (NASDAQ:FGEN) Trading Up - Insiders Selling, Short Interest Growing - Finance Daily (NASDAQ:FGEN) - July 30 at 5:40 AM logoExpected For FibroGen, Inc (NASDAQ:FGEN) Sales Of $1071.09 - Investor Newswire (NASDAQ:FGEN) - July 29 at 5:08 PM logoFibroGen, Inc (NASDAQ:FGEN) Trading Up – Insiders Selling, Short Interest Growing (NASDAQ:FGEN) - July 28 at 9:32 PM logoAstellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in ... (NASDAQ:FGEN) - July 26 at 5:59 AM logoAstellas and FibroGen Announce First Patient... (NASDAQ:FGEN) - July 25 at 10:34 PM logoAstellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results … (NASDAQ:FGEN) - July 25 at 10:34 PM logoAstellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan (NASDAQ:FGEN) - July 25 at 9:28 PM
News IconIt Seems FibroGen Inc Will Go Up. Have Big Gap Up Today - Consumer Eagle (NASDAQ:FGEN) - July 21 at 10:33 PM
News IconFibroGen, Inc (NASDAQ:FGEN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:FGEN) - July 21 at 10:33 PM
News IconCould FibroGen Inc Lose Strenght? The Stock Increases A Lot Today - Consumer Eagle (NASDAQ:FGEN) - July 21 at 8:32 AM logoFibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : July 21, 2016 (NASDAQ:FGEN) - July 21 at 8:08 AM


FibroGen (NASDAQ:FGEN) Chart for Friday, October, 21, 2016

Last Updated on 10/21/2016 by Staff